Data / Drug companies / Tablet, for suspension
Companies that list tablet, for suspension products: 36 companies and 84 products in the FDA NDC directory
The FDA National Drug Code Directory lists 84 products that are tablet, for suspension products from 36 companies. The ten largest listers hold 47.6% of them, and the newest started marketing on October 26, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies
- 36
- Products
- 84
- Drugs by generic name
- 15
- Main marketing category
- Generic drugs (ANDA)
Companies that list tablet, for suspension products
Ranked by number of products in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | tablet, for suspension | New drug applications (NDA) | March 16, 2023 |
| Alembic Pharmaceuticals Inc. | 5 | tablet, for suspension | Generic drugs (ANDA) | November 21, 2019 |
| Alembic Pharmaceuticals Limited | 5 | tablet, for suspension | Generic drugs (ANDA) | November 21, 2019 |
| Aprecia Pharmaceuticals, LLC | 4 | tablet, for suspension | New drug applications (NDA) | February 5, 2016 |
| Novartis Pharma Stein AG | 4 | tablet, for suspension | Drugs for further processing | March 16, 2023 |
| Amneal Pharmaceuticals NY LLC | 3 | tablet, for suspension | Generic drugs (ANDA) | January 14, 2025 |
| Ani Pharmaceuticals, Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | October 10, 2025 |
| Ascend Laboratories, LLC | 3 | tablet, for suspension | Generic drugs (ANDA) | November 22, 2019 |
| Biocon Pharma Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | January 14, 2026 |
| Bionpharma Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | September 28, 2018 |
| Breckenridge Pharmaceutical, Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | January 28, 2025 |
| Dr. Reddy's Laboratories Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | November 20, 2019 |
| GlaxoSmithKline LLC | 3 | tablet, for suspension | New drug applications (NDA) | October 12, 2000 |
| Glenmark Pharmaceuticals Inc., USA | 3 | tablet, for suspension | Generic drugs (ANDA) | January 6, 2020 |
| MSN Laboratories Private Limited | 3 | tablet, for suspension | Generic drugs (ANDA) | November 20, 2019 |
| Novadoz Pharmaceuticals LLC | 3 | tablet, for suspension | Generic drugs (ANDA) | November 20, 2019 |
| Sun Pharmaceutical Industries, Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | December 2, 2019 |
| Teva Pharmaceuticals, Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | November 1, 2024 |
| Janssen Products, LP | 2 | tablet, for suspension | New drug applications (NDA) | February 27, 2026 |
| Prasco Laboratories | 2 | tablet, for suspension | Authorized generics (NDA) | January 20, 2025 |
| Actelion Pharmaceuticals US, Inc. | 1 | tablet, for suspension | New drug applications (NDA) | July 29, 2021 |
| Burel Pharmaceuticals, LLC | 1 | tablet, for suspension | Generic drugs (ANDA) | December 19, 2022 |
| E.r. Squibb & Sons, L.L.C. | 1 | tablet, for suspension | New drug applications (NDA) | September 15, 2025 |
| Eton Pharmaceuticals, Inc. | 1 | tablet, for suspension | Generic drugs (ANDA) | December 20, 2021 |
| Glaxo Operations Uk Ltd | 1 | tablet, for suspension | Drugs for further processing | June 12, 2020 |
| Global Blood Therapeutics, Inc, a Subsidiary of Pfizer Inc. | 1 | tablet, for suspension | New drug applications (NDA) | December 17, 2021 |
| Lupin Pharmaceuticals, Inc. | 1 | tablet, for suspension | Generic drugs (ANDA) | August 18, 2025 |
| Navinta LLC | 1 | tablet, for suspension | Generic drugs (ANDA) | August 1, 2022 |
| Patheon Inc. | 1 | tablet, for suspension | Drugs for further processing | December 17, 2021 |
| Pfizer Ireland Pharmaceuticals Unlimited Company | 1 | tablet, for suspension | Drugs for further processing | January 22, 2025 |
| Rare Thyroid Therapeutics International AB | 1 | tablet, for suspension | New drug applications (NDA) | October 26, 2026 |
| Recordati Rare Diseases | 1 | tablet, for suspension | New drug applications (NDA) | March 18, 2010 |
| SpringWorks Therapeutics, Inc. | 1 | tablet, for suspension | New drug applications (NDA) | February 11, 2025 |
| ViiV Healthcare Company | 1 | tablet, for suspension | New drug applications (NDA) | June 12, 2020 |
| Zydus Lifesciences Limited | 1 | tablet, for suspension | Generic drugs (ANDA) | February 17, 2026 |
| Zydus Pharmaceuticals USA Inc. | 1 | tablet, for suspension | Generic drugs (ANDA) | February 17, 2026 |
Drugs most often listed
| Drug | Products here | Companies listing it |
|---|---|---|
| Levetiracetam | 6 | 87 |
| Lamotrigine | 5 | 51 |
| Deferasirox | 33 | 21 |
| Everolimus | 15 | 15 |
| Apixaban | 1 | 8 |
| Bosentan | 4 | 7 |
| Carglumic acid | 4 | 4 |
| Darunavir ethanolate and cobicistat | 1 | 2 |
| Dolutegravir sodium | 1 | 2 |
| Lamotrigine chewable dispersible | 2 | 1 |
| Dabrafenib | 1 | 1 |
| Mirdametinib | 1 | 1 |
| Rilpivirine hydrochloride | 1 | 1 |
| Tiratricol | 1 | 1 |
| Voxelotor | 1 | 1 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.